18/11/2025
ππ£ππππ©πππ‘π ππ§ππ (πππ£ππππ₯ππ«ππ§) ππ¨ πππ§π!
In a huge boost to Eswatini's efforts to sustain and improve the gains made in HIV response, the Ministry of Health has today officially received the first batch of Lenacapavir (LEN) injectable PrEP, courtesy of Global Fund, being among the first two African states to get the groundbreaking HIV prevention drug.
Minister Appolo Maphalala, representing Minister Mduduzi Matsebula, welcomed the LEN from The Global Fund Executive Director Peter Sands, at a ceremony attended by Daniel 0βDay, Chairman and CEO of LEN manufacturers Gilead Sciences, and US Embassy Charge dβAffaires Marc Weinstock, among other dignitaries from local and international partners. The batch is at the Central Medical Stores and will be rolled out after the official launch scheduled for World AIDS Day commemoration, 1 December. The roll-out will be supported by the United States Government with more batches of Lenacapavir yet to come.
Minister Maphalala: "Lenacapavir ushers in a new era of possibility. As a long-acting injectable administered just twice a year, it offers a discreet, convenient, and highly effective method of HIV prevention. For many of our citizens, particularly those who face challenges with daily pill-taking, frequent clinic visits, or stigma, this innovation represents more than a medical breakthrough β it is a lifeline."
Peter Sands: "Today, we mark another historic milestone. I want to congratulate Eswatini for being among the first two low- and middle-income countries on the continent to receive lenacapavir... The Global Fund remains fully committed to supporting Eswatiniβs HIV response and ensuring that innovations like lenacapavir reach those who need them most."